Shire’s Request For ProAmatine Hearing Will Go Unanswered Until 2012

More than a year after Shire formally requested a public hearing on the Center for Drug Evaluation and Research’s proposed withdrawal of the hypotension drug ProAmatine (midodrine), FDA says it needs more time to consider the issue.